During the preconception phase, the nurse should teach about which infectious diseases as risk factors for maternal complications? (Select all that apply).

Choice A rationale:

A respiratory rate of 10 bpm is significantly lower than the normal range for adults, which is typically 12-20 breaths per minute. This finding suggests respiratory depression, a potential complication of magnesium sulfate administration. Magnesium sulfate, when given intravenously, can lead to respiratory depression, hypotension, and loss of deep tendon reflexes. Monitoring respiratory rate is crucial to detect early signs of respiratory depression, allowing prompt intervention to prevent respiratory failure.

Choice B rationale:

A blood pressure of 148/94 mmHg is elevated and indicates hypertension. While hypertension is a known side effect of magnesium sulfate, a blood pressure reading alone is not specific enough to indicate a complication of treatment. It is essential to consider other vital signs and symptoms for a comprehensive assessment.

Choice C rationale:

Deep tendon reflexes of +2 are within the normal range and do not indicate a complication of magnesium sulfate administration. Hyperreflexia (exaggerated reflexes) is a sign of magnesium toxicity, but +2 reflexes are normal. Monitoring deep tendon reflexes is crucial, but the given value is within the normal range.

Choice D rationale:

An urine output of 70 ml/hour is within the normal range of urine output (30-60 ml/hour) for adults. While monitoring urine output is essential to assess renal function, this value does not indicate a complication of magnesium sulfate administration. Decreased urine output could suggest kidney injury, which is a potential complication of magnesium sulfate, but 70 ml/hour is within the normal range.

Choice A rationale:

The first dose of the immunization for Measles, mumps, and rubella (MMR) is typically given at the age of 1 year. This timing is in line with the recommendations from organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Administering the MMR vaccine at this age ensures early protection against these contagious diseases. Delaying the vaccine could put the child at risk, especially considering the highly infectious nature of measles.

Choice B rationale:

Administering the MMR vaccine at 18 months is not in line with the recommended immunization schedule. Waiting until 18 months might expose the child to the risk of contracting these diseases during the gap period, as maternal immunity wanes after the first few months of life.

Choice C rationale:

Administering the MMR vaccine at 2 years is later than the recommended age. Waiting until 2 years could leave the child vulnerable to these diseases during the time between birth and the administration of the vaccine. Early immunization, starting at 1 year, provides essential protection during this critical period.

Choice D rationale:

Waiting until 4 years to administer the MMR vaccine is not in line with the standard immunization schedule. Delaying the vaccine until 4 years of age leaves the child susceptible to these diseases for a more extended period, which is not recommended for preventing outbreaks and ensuring community immunity. The first dose of the immunization for Haemophilus influenzae type B (Hib) is given at the age of 2 months.